lystn

Microbiologist and virologist, Dr Gagandeep Kang speaks with Kiran Mazumdar-Shaw, the founder-chairperson of one of India’s largest pharmaceutical companies, about India’s flawed vaccine roll-out, and the trade-offs between patents and pricing. 

Highlights

• India’s vaccine roll-out programme: How does one decide who gets priority and who does not?
• What does the Indian government need to do to ensure vaccines are affordable and available for everyone?
• What role should the private sector play in India’s vaccine roll-out programme?
• Should COVID-19 vaccines be protected by patents? 

For more information about IDR, go to www.idronline.com. Also, follow IDR on Facebook, Linkedin, Twitter and Instagram.

Read more

1. India’s COVID-19 vaccine drive is excluding millions of citizens
2. India’s COVID-19 response limited by strong urban and tech bias
3. Fighting the pandemic: Two contrasting approaches[T1]
4. How rebuilding trust in the public healthcare system can help combat vaccine hesitancy in rural communities
5. A ‘corona demon’ raises awareness about COVID-19 in rural Andhra Pradesh
6. A pathway to universal healthcare in India
7. Engaging communities is critical to the COVID-19 response
8. Is the COVID-19 vaccine in India a public or a private good?
9. Upholding trust in vaccination
10. Covid-19 Pandemic: Shortages, Hesitancy and Pricing Plague India’s Covid-19 Vaccination Programme
11. All work, no vaccines: Security guards and COVID-19
12. Learn more about the Coalition for Epidemic Preparedness Innovations or Cepi
13. ‘None are safe until all are safe’: COVID-19 vaccine rollout in low- and middle-income countries
14. Covid: The vaccine patent row explained

This podcast is a Maed in India production, you can find out more about us https://www.maedinindia.in/